Dear Colleagues/ Agents / Distributors,

The growing outbreak of COVID-19 has affected each one of us in multiple ways, our families, friends, businesses and way of life. This fast-changing situation has forced us to re-evaluate how we operate. At Taj Pharmaceuticals, we are working on using this challenge as an opportunity to make our company more dedicated, more efficient, and more focused on serving the needs of our clients, a better company to partner with in our common mission of bringing healthcare treatments to market faster and of improving outcomes for patients. To manage through the crisis, we have established a new agile generics supply governance cadence. Our CEO Generics Supply Center meets daily at 4 p.m. EDT and maintains coordination with each of our Global Business Unit and Regional level Generics Supply Centers, as well as our Medical & Scientific Task Force, IT Task Force, HR Task Force and Finance Task Force. In this letter, we would like to update you as a leadership team on how we are managing this crisis and helping the healthcare industry respond to its challenges.

Putting safety first. Our first priority is the safety of staff and the patients, healthcare professionals, customers and suppliers we frequently interact with. To limit exposure, we have prohibited international travel, closed facilities and asked most of our staff to work remotely. We have added bandwidth and VPN capacity to our advanced infrastructure to avoid service disruptions. To date, this transition has gone smoothly. Our data production centers remain fully operational and our technology, analytics, primary market research and real-world deliveries continue in the ordinary course per existing business continuity plans.

Minimizing disruption to clinical trials. As supply chains are disrupted, as clinics and hospitals become inaccessible or as it becomes sometimes unsafe or difficult for patients to travel, we are doing everything in our power to ensure science and innovation do not stop. The situation is fluid and we have been monitoring daily, and sometimes hourly, each trial, each site, each enrolled patient, to maintain the integrity of our ongoing trials. We are coordinating closely with local health authorities and customers to deploy, when appropriate and feasible, our services and technologies to further increase remote-based CRA and centralized monitoring for trials, remote patient visits (aka virtual trials), supply logistics and other remote interactions between patients and HCPs. We are currently transitioning significant portions of trials to our Study Hub Virtual Trial execution platform, including Televisit, digital interaction and more, to enable study continuity on a global basis.

Helping organizations plan & manage for the outbreak. We are applying our people, data and technology, to bring AI and insights to help accelerate responses and planning efforts. We have provided data scientists with information and tools to understand the rapidly evolving dynamics of the outbreak to predict how things will develop. We are rolling out new remote-detailing solutions and workflows to support remote-based working. In Japan and Italy, for example, we are creating AI-powered forecasting tools that are helping predict the progression of COVID-19 ? this will expand to other countries in Europe soon. In the UK, we are providing analytics and staff who are physically working side-by-side with government officials to help monitor the drug supply chain. And in the India, we are working with key central agencies to provide data and insights that will help them manage capacity and demand across the health system.

Helping accelerate the development of COVID-19 treatments and vaccines. Lastly, we are joining the global response to the crisis and contributing our resources to its resolution by providing Taj Pharmaceuticals staff, technology and expertise to support the development of new treatments. In Asia, we are providing an Taj Pharmaceuticals team to help develop two new treatments for COVID-19 using existing HIV and flu vaccines. In India, we are partnering with academic institutions to develop new lab tests to identify vaccine candidates quicker than currently available tests. And in Europe, we are collaborating with governments and the pharmaceutical industry to develop several experimental vaccine candidates using our Prime Site networks and data assets to accelerate timelines. If successful, all of these will bring much-needed treatments to patients quickly.

We would like to end this letter with a message there is light at the end of the tunnel. This outbreak is extraordinary in terms of scale, speed, and uncertainty but there is reason to be optimistic. The Chinese National Health Commission recently reported almost no new domestic cases, approximately 60% of hospitals outside of Hubei Province are now accessible to patients, schools are slowly reopening and life beginning to normalize. Even with the recent turmoil, we are still expecting growth in the Chinese pharmaceutical market this year. Given all these signs, we are hopeful that by end of May, China will almost fully recover. You will find our latest update, insights and analysis on the situation in China by clicking HERE.

In these most unusual of circumstances, Taj Pharmaceuticals is renewing its commitment to becoming a better partner to you, to marshal all our talents and resources at the service of the greater cause we all work for, to benefit the health and wellbeing of patients everywhere. We will continue be here to help you accomplish this objective during and after this crisis is over. Please do not hesitate to call on any one of us for any reason. We wish you and everyone around you the best of health and look forward to meeting and engaging with you and your teams in-person soon.

Stay safe, stay healthy, stay in touch.

Warm regards,

Abhishek Kumar Singh
CEO? Taj Pharma Group
Taj Pharmaceuticals Limited
Help Line: +91 8448444095
Toll Free No: 1800?222?434 (Ext 3 International Dept.)

COVID-19 IMPORTANT UPDATE ? TAJ PHARMACEUTICALS (21/03/20)

As the global situation around coronavirus (COVID-19) continues to evolve we wanted to share with you the steps Taj Pharmaceuticals is taking to ensure the well being of our customers, team members and the wider community.

Whilst the number of reported cases in India is still relatively low, we have implemented the following precautionary measures:

Work spaces are being regularly disinfected and sanitized
Body temperatures are checked as employees enter office
Hand sanitizer is available to all on office premise
All employees are asked to wear mask at all times
Work from home has been given to those employees where possible
All outstation travels, personal meetings & visits have been restricted
Employees have been educated regarding regular hand washing, avoiding close contact with others (particularly those with flu-like symptoms) and self-isolating if symptoms present themselves
We continue to actively monitor and act on all health and travel advice issued by Indian and relevant global governments and health departments

We will continue to observe caution and play our part in limiting the spread of the infection. Taj Pharmaceuticals Limited wishes you and everyone, good health and safety.

The health and safety of our employees, clients, and candidates is of utmost importance to PSI. We have an internal task force that now meets each business day to monitor the situation with Novel Coronavirus (COVID-19), and we are in close communication with our testing partners around the world.

COVID-19: Updates for Our Customers

A MESSAGE FROM TAJ PHARMA CEO ABHISHEK KUMAR SINGH

As the novel coronavirus (COVID-19) situation continues to evolve and business impacts are becoming more far reaching across every sector, I wanted to share what we are doing at Taj Pharmaceuticals to ensure the continuity in our support of you and the animals in your care. Read more

CUSTOMER SUPPLY AND SERVICE

At this time, there is no direct impact to Taj Pharmaceuticals supply, and we continue to monitor closely with distributors.

If the situation evolves, we have a robust 4?6 months inventory on key products.
Border controls are evolving along with the situation, region by region. Taj Pharmaceuticals has a well-established process to assess and act quickly on these developments and restore operations to normal levels and mitigate further impact to the business.
Taj Pharma is monitoring all cargo movements and transportation lanes to ensure successful movement of goods throughout our network.

At this time, all of our manufacturing sites around the world remain open. With the health and safety of our colleagues as our top priority, we are taking great care to ensure continuity at all our manufacturing sites.

If we need to close a site, Taj Pharmaceuticals will leverage its global network and work proactively to ensure manufacturing capabilities meet customer needs.
We are complying with all local government recommendations for social distancing with flexible work arrangements.

Across our global network, formal plans are underway within our Global Manufacturing & Supply team to bolster our inventory and availability through:

Increased inventory positions for all aspects of our supply chain: Finished Goods, Active Ingredients and supporting components.
Deployment of inventory from regional hubs to market-specific warehouses.

Our field sales and technical representatives are available remotely.

If you require an in-person visit from one of our representatives, please be assured they are following the health and hygiene guidance from the World Health Organization and Centers for Disease Control and Prevention.
If you work with a Taj Pharmaceuticals representative, please reach out to him or her as your first point of contact. Otherwise, please contact us here.

ANIMALS AND COVID-19

Pets

According to the World Health Organization and the U.S. Centers for Disease Control & Protection, there is no evidence that companion animals or pets such as cats and dogs can spread the virus that causes COVID-19.

Infectious disease experts and multiple international and domestic human and animal health organizations agree there is no evidence at this point to indicate that pets can become ill with COVID-19 or spread COVID-19 to people or other animals. (AVMA)

If a person becomes ill with COVID-19, out of an abundance of caution, WHO and CDC recommend limited contact with animals and that another member of the household take care of walking, feeding, and playing with pets. If an ill person must care for pets or has a service animal, it is recommended that they wear a facemask; don?t share food, kiss, or hug them; and that they practice handwashing before and after contact with pets.

For more information on risk to companion animals, read the statement from the World Small Animal Veterinary Association.

Livestock

According to the Friedrich Loeffler Institute (FLI), the National Institute for Animal Health in Germany, there is currently no evidence that farm animals can contract the SARS-CoV-2 coronavirus (COVID-19) or that livestock can transmit and spread it.

Food

Public health officials and academics agree that the coronavirus poses little danger from a foodborne illness perspective. (Food Safety News)

Coronaviruses are generally thought to be spread from person-to-person through respiratory droplets. Currently there is no evidence to support transmission of COVID-19 associated with food. Before preparing or eating food it is important to always wash your hands with soap and water for 20 seconds for general food safety. Throughout the day wash your hands after blowing your nose, coughing or sneezing, or going to the bathroom. (CDC)

What Taj Pharmaceuticals is Doing

Through the Taj Pharma Center for Transboundary and Emerging Diseases, our infectious disease scientists are evaluating technical reports in this rapidly evolving situation to understand if the novel coronavirus is a specific risk to livestock and pets. In response to outbreaks of infectious diseases, the Center mobilizes resources from across our company and works closely with leaders from government, health organizations and the veterinary and livestock agricultural communities to identify disease threats to animals. The Center harnesses our capabilities in vaccine development, alliances with centers of excellence, regulatory affairs and flexible manufacturing capacity.

WHAT WE ARE DOING FOR TAJ PHARMACEUTICALS COLLEAGUES

Since the outbreak began in early January, we have maintained a coordinated response across our global sites to prioritize the safety of our colleagues, the service of our customers, and the quality of our products. Caring for our colleagues is our top priority because we know they make all the difference to customers and we depend on them to deliver our medicines and products. We are following the health guidance of the World Health Organization and the Centers for Disease Control and Prevention at our sites and providing that guidance to our colleagues. We are being flexible with our work and implementing remote and staggered schedules where appropriate, as well as offering colleagues the flexibility to care for their health and families.

Taj Pharmaceuticals Closures

As the COVID-19 outbreak continues to spread throughout the communities where we live and work, in order to continue to help protect the health and safety of our candidates, clients, and employees, we have made the difficult decision to temporarily close our owned and operated physical manufacturing units in India starting end of day March 19, and in the United Kingdom starting end of day March 20, until April 13.

We also continue to monitor all our partner sites around the world and adhere to closures based on country and local requirements.

Rescheduling

Effective immediately, candidates can reschedule up to and including the day of testing at no penalty and no documentation required. NOTE: In most cases, candidates can reschedule their examinations on-line and they are encouraged to do so. If a candidate chooses to reschedule through our candidate support call centre, they may experience longer than usual wait times under the current circumstances.

Candidates that are a part of an eligibility programme will be provided guidance if a new eligibility is required in order to reschedule and how to obtain it.

We are obtaining guidance from our client to support candidates who must test within a specified period and how we are able to accommodate them.

All reschedule rules and no show policies are relaxed through April 30th.
If you are unable to make your exam and you are reported as a no-show you will be allowed to reschedule at no cost.
In the event that there are restrictions based on eligibility periods or test windows we will work on options with your examination sponsor.?

The week of March 21st, a guest at our hotel preliminarily tested positive for COVID-19. With 21c?s first priority first being the safety of our team, our guests and our community, we did temporarily shut down the company, units, and labs. During this shutdown, we completed a comprehensive, company-wide deep clean with a third party company. With the deep clean complete, we re-opened our doors on March 31st.

The Company Taj Pharmaceuticals will continue to work with a global team of experts in hygiene and safety, heightening our already vigorous hygiene and prevention measures, with enhanced cleaning procedures and EPA-registered disinfection products with proven efficacy in killing respiratory viruses, including COVID-19.

Taj Pharmaceuticals : Our commitment to clients in the spread of COVID-19

We Taj Pharmaceuticals are in the midst of challenging times, brought upon us due to the unimaginable spread of COVID-19. As we grapple with this difficult and ever evolving situation, we wanted to reach out to make sure that you are doing okay and in case you needed any help. It is hard to think of a business that is not impacted by this pandemic, the effects of which we will all continue to feel for a long time.

As a firm, we have always placed the highest emphasis on delivering quality generics to all our clients, consistently. I want to take this opportunity to assure you that our professional commitments continue to occupy an important place for all of us at Taj Pharmaceuticals even as we steer our way through the crisis. Our Values of Care and Working Together come to fore in difficult times like these ? we want to be responsible towards you, as well as our people and the larger society that we are a part of.

We Taj Pharmaceuticals have put in place several measures that are helping us address this situation. Earlier this week, we announced that our people would work from home until further notice or unless there is a critical business need. We have also discontinued all international travel and physical meetings for the time being.

We Taj Pharma have been able to make this decision on the back of a robust infrastructure and processes that we have put in place over the past few years, which enable us to continue providing seamless service to our clients without the need to be physically present in office. Accordingly, we are also working with our clients to assess where our teams can be moved to a virtual working space.

I want to give you the confidence that we have tested our Business Continuity processes and at no time, do our clients need to be concerned about our ability to service them seamlessly.

In this difficult time, we have witnessed some heartening examples of enduring human spirit and this gives me the belief that together we will overcome this.

I thank you for your continued support and we at Taj Pharmaceuticals, assure our continued support to you and your teams as we together navigate these challenging times.

Take care and stay safe.

Warm regards,

Abhishek Kumar Singh
CEO| Taj Pharmaceuticals India

Important message from Mr.Shantanu Kumar Singh

Dear Customer,

I {Shantanu Kumar Singh ? Executive Director of Taj Pharmaceuticals Limited} trust this letter finds you and your loved ones safe & healthy.

The last few weeks have been quite eventful with the proliferation of COVID-19 to different parts of the world. India with the second largest population in the world has a formidable challenge ahead of it. While the government agencies are doing their best in responding to the situation through various initiatives such as ?Janta Curfew?, we as responsible citizens should do our bit to help our communities in staying safe.

As you may be aware, the virus has also left an impact, not just on global Pharmaceuticals markets at a macro level but also small communities at a micro level. The Pharmaceuticals markets in India too, have reacted to this global phenomenon. However, we would like to assure you that Taj Pharmaceuticals Limited will be by your side as we navigate through these turbulent times.

I would like to take this opportunity to apprise you of the necessary steps taken by Taj Pharmaceuticals to protect you, our customer and our colleagues.

As a first step, we have secured our facilities and staff to minimize any internal or external exposure to COVID-19. Our Generics Distribution Plan has ensured that our urgent day-to-day distribution continue seamlessly and without inconveniencing our medical agents. The safety and well-being of our customers and our colleagues are paramount to us.

Our 1500+ Generic branches* and 2400+ Generic Out lets* across India and Dubai continue to be operational and we are in compliance with all the necessary directives as issued by the World Health Organisation (WHO) and various other government agencies.

As a brand we always work towards taking an inclusive approach to our services by welcoming all our customers to our branches. However, in light of the current situation we would like to suggest that you visit Generic Pharmacies only when absolutely necessary.

Our world-class Online Pharmacies and Mobile Pharmacy solutions / Online Pharmacies will enable you to use buy urgent generics products and services from the safety and comfort of your home. While our pharmacies customer contact center is available 1800 222 434, keeping in mind the safety of our colleagues, it is currently operational with reduced staff strength.

We are always grateful for the confidence that our importers / agents / customers and investors have placed in us. This trust and patronage reflects in the robust business metrics of Taj Pharmaceuticals Limited. Our Generics Storage Ratio and urgent medical supplies are above the industry average.

I would like to reiterate that your safety and wellbeing are paramount to us and we remain committed to providing you with world class generic medicine products and services. We look forward to your patronage and support as always in these ?new normal? times.

Stay safe, stay healthy, stay in touch.

Warm regards,

Shantanu Kumar Singh
Executive Director ? Taj Pharma Group
Taj Pharmaceuticals Limited

2019-nCoV COVID-19 IgM/IgG Rapid test kit

OVID-19 IgG/IgM Rapid comboTest

COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a solid phase immunochromatographic
assay for the rapid, qualitative and differential detection of IgG and IgM antibodies to 2019 Novel Coronavirus in human whole
blood, serum or plasma.

Features & Benefits

? Fast results as soon as 2?10 minutes ? Facilitates patient treatment decisions quickly ? Simple, time-saving procedure ? Little specimens, only 5 ?L of serum/plasma or 10 ?L of whole blood specimens ? All necessary reagents provided & no equipment needed ? High sensitivity and specificity

For confirmed coronavirus disease 2019 (COVID-19) cases, reported illnesses have ranged from mild symptoms to severe illness and death. Symptoms can include:

Fever ? Cough ? Shortness of breath

The virus is thought to spread mainly from person-to-person.

Between people who are in close contact with one another (within about 6 feet). ? Via respiratory droplets produced when an infected person coughs or sneezes. ? These droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs.

TAJ PHARMA started working on mRNA vaccine against coronavirus

Taj Pharmaceuticals Biotechnological Division has announced the research in order to create an mRNA vaccine against SARS-COV-2 (coronavirus). Development will be based on previous pipelines for mRNA-oncovaccines creation: an area where the company has a great expertise. The first animal studies are scheduled for the end of April.

According to Abhishek Kumar Singh, TAJ PHARMA CEO, today the whole world is working on the search for coronavirus treatment: ?By now, 66 companies around the world have announced the development of drugs against SARS-COV-19, 51 of them are working on vaccines, 15 ? on DNA, RNA or small molecules based drugs. In my opinion, the more intellectual forces are involved in solving the problem, the sooner the world can get over this challenge?.

Three vaccine options are planned to be developed; and animal testing is scheduled for late April. The short development period is granted by its mRNA basis. In contrast to the traditional vaccines based on reorganized proteins, manufacturing of small molecules drugs takes less than five to six months.

Since the end of January, researchers from the Dongfang Hospital at Shanghai Tongji University and the Chinese biotechnology company Stemirna have been working on the vaccine. They synthesized matrix ribonucleic acid (mRNA) with several sequences of different antigens. Recently, researchers from the University of Utrecht (Netherlands), in collaboration with the Erasmus University Medical Center and Harbor Biomed, reported the discovery of the first human monoclonal antibody that can block the attachment of the SARS-CoV-2 coronavirus that causes Covid-19.

About the company

Taj Pharmaceuticals is the global leader in generics and one of the India?s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients? needs. Taj Pharmaceutical?s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.

Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world. At Taj Pharmaceuticals, Taj Pharma India have pursued this mission with patience, dedication, imagination and skill, for over a century. Taj Pharma vision is to develop targeted medicines and diagnostic tools that combine to offer patients, physicians and payers better, safer, more cost-effective healthcare.

Once again, welcome to Taj Pharmaceuticals, a great company that is translating a great vision into reality ? We Innovate Healthcare.

Taj Pharmaceuticals Limited is committed to earning the trust of doctors, patients and customers every day. Taj Pharma colleagues worldwide believe that trust is not easily granted, and that is the reason Taj Pharma India focus each day on becoming a champion for Taj Pharma stakeholders.

During the past ten years, Taj Pharmaceuticals Group has been building a new kind of health care company. Throughout Taj Pharma Group (India), there?s a desire to build long-term relationships with Taj Pharma stakeholders based on mutual confidence. This is evident in many ways. Taj Pharma scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and overall well-being of people around the world. Taj Pharma sales professionals, marketing teams, colleagues working at Taj Pharma plants and others throughout the organization at all levels of responsibility take each day as a fresh opportunity to earn trust.

All of this takes hard work, sharp execution, integrity and transparency on the part of Taj Pharmaceuticals Group colleagues. Taj Pharma global team is working to sustain and expand innovative new treatments. Taj Pharma India?re determined to do Taj Pharma part to increase access to better health care for all people. And, Taj Pharma India is focused on becoming the best in three key strategic areas: people, products and processes.

Taj Pharma India?re beginning to see the results of Taj Pharma efforts, but believe the best is yet to come. The test of being a true champion is to never give up and to passionately strive for even better outcomes. From Taj Pharma perspective as a health care company, that means helping people around the world live better and live longer.

Stay on top of the pandemic

Immune response: This is what?s happening in your body when you have coronavirus.
Staying home: Confused about ?shelter in place?? Read this.
Growing research: This is how long coronavirus survives on hard and soft surfaces.
FDA approval: Some good news about testing.

Stay current with comprehensive, up-to-the-minute information, all in one place, at the new Medium Coronavirus Blog. Sign up for our Coronavirus newsletter here.

Labels: Covid-19, COVID-19 treatments, COVID-19 tests, Coronavirus Cases in India, Coronavirus Latest updates, Coronavirus News, COVID-19 trials, Coronavirus treatments, COVID-19 treatments, COVID-19 clinical trials, coronavirus ongoing trials, Coronavirus breaking news, Coronavirus updates, Coronavirus new cases, coronavirus outbreak, COVID-19 coronavirus